← Back to Clinical Trials
Recruiting NCT01915225

NCT01915225 Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01915225
Status Recruiting
Phase
Sponsor National Cancer Institute (NCI)
Condition Colorectal Neoplasms
Study Type OBSERVATIONAL
Enrollment 1,800 participants
Start Date 2013-07-21
Primary Completion 2035-06-30

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,800 participants in total. It began in 2013-07-21 with a primary completion date of 2035-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: \- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC). Objectives: \- To collect tissue samples for use in studying new ways to treat tumors. Eligibility: * Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC. * Children under the age of 18 but who are older than 2 years of age are eligible to be enrolled on the research sample collection portion of this study if they will have a biopsy or surgery as part of their medical care. Design: * Before their procedure, participants will have a small blood sample taken. * Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3-4 hours. * For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis. * Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.

Eligibility Criteria

* INCLUSION CRITERIA: * Participants must be 2 years of age or older. Note: Participants greater than or equal to 2 and \< 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the biospecimen sampling (e.g., blood, urine, ascites, bile, or \[clinically indicated\] resected tumor tissue) does not add risk to the clinically indicated procedures. * Participants who have premalignant, primary, or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological/cytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment, and/or follow-up. * Participants without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated. * Participants should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery. * Participants must be planning to undergo surgery or biopsy as part of their normal treatment plan. * Ability of participant, parent/guardian or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: None.

Contact & Investigator

Central Contact

Cathleen E Hannah, C.R.N.P.

✉ foregut@mail.nih.gov

📞 (240) 858-7006

Principal Investigator

Jonathan M Hernandez, M.D.

PRINCIPAL INVESTIGATOR

National Cancer Institute (NCI)

Frequently Asked Questions

Who can join the NCT01915225 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, studying Colorectal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01915225 currently recruiting?

Yes, NCT01915225 is actively recruiting participants. Contact the research team at foregut@mail.nih.gov for enrollment information.

Where is the NCT01915225 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT01915225 clinical trial?

NCT01915225 is sponsored by National Cancer Institute (NCI). The principal investigator is Jonathan M Hernandez, M.D. at National Cancer Institute (NCI). The trial plans to enroll 1,800 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology